Join me Wednesday, March 26 for Endpoints News inaugural science-focused event, Endpoints Catalysts, where I'll be interviewing leaders in CRISPR gene editing, cell atlases + spatial biology, and regenerative medicine. events.endpts.com/catalysts25

Akido Labs, a California health tech startup, is letting AI take the reins in doctor's visits, all the way from intake to diagnosis to treatment plans. Here's how: endpts.com/how-akido-labs…

llumina cracked the DNA code. Now the company, and firms led by ex-Illumina employees, are steering into the buzzy multiomics field. Via Endpoints News endpts.com/illuminas-ceo-…

THREE Neal Award finalists for Endpoints News this year including our already-award-winning health tech newsletter from Ngai Yeung, Lydia Ramsey Pflanzer and Shelby Livingston, AI coverage from Andrew Dunn and a package of R&D stories from myself, Jared Whitlock and Ryan Cross the Science Boss.

✨Imagine a place where the biotech market is up, deals are happening, and there are even (DARE TO DREAM) IPOs ✨ endpts.com/chinas-biotech…

$13 billion MA startup Devoted Health grew revenue to $3.3 billion in 2024 and shrank its operating losses, according to my analysis of state insurance filings. endpts.com/devoted-health…

New: As confidence in the FDA wavers, US drugmakers are increasingly looking abroad for clinical trials. I spoke with companies, consultants and others about the trend. Via Endpoints News endpts.com/us-drugmakers-…

It's an honor to be recognized as a finalist by NIHCM for my reporting on a teenager's custom medicine, and the broader story of rare disease research. nihcm.org/news/finalists…

Big one from Shelby Livingston out today Endpoints News -- the result of a monthslong investigation

🏆~Another~ big congrats to the Endpoints News team for two more awards! This time two win's at the SIIA Neal awards, for Andrew Dunn + our health tech team Lydia Ramsey Pflanzer Shelby Livingston + Ngai Yeung!!!

The Endpoints News health tech newsletter was highlighted for the great, incisive intros that our team writes twice a week, adding valuable perspective on the industry.

🪙You've heard of the PayPal Mafia. 🧬Now meet the Illumina-ti $ILMN endpts.com/how-illuminas-…

Can a drug developed for one person's rare form of ALS become a treatment for many others? A treatment made just for a 26-year-old woman offers a glimpse into how customized therapies could be just a starting point. endpoints.news/a-custom-als-d…

Exclusive: FDA's Makary sought rejection of KalVista’s drug in an unusual move by commissioner, sources say My latest — endpoints.news/sources-fda-ch…

One biotech VC calls China a threat. Another says Americans won’t forgive politicians who impede life-saving drugs. Inside the investor split on China’s ascent in drug development. endpoints.news/us-investors-d… w/ Andrew Dunn + Max Bayer, Kyle LaHucik

Wearables for everyone? I dug into the evidence behind the health tools RFK wants all Americans to use. endpoints.news/the-trump-admi…

🎙️🚀Today at 12:15pm ET, we're talking to Varda Space Industries about whether — after years of hype — this is the moment when "drugs in space" moves from science project to a real industry. Join me, Ryan Cross the Science Boss + Varda CSO Adrian Radocea in a few hours! endpoints.news/endpoints-live…

We are closely reporting on Sarepta Therapeutics and the FDA's request to stop selling its Duchenne treatment If you have any tips, please contact me on Signal at jaredwhitlock.73, including if you work at Sarepta or were recently let go in this week's layoffs.

Peter Marks -- who controversially helped push through Sarepta's therapy -- tells Max Bayer that pausing sales of Elevidys makes sense. Exclusive here: endpoints.news/peter-marks-sa…

Sarepta halts US shipments of Duchenne therapy, bowing to FDA endpoints.news/sarepta-halts-…